The results of the metabolic profiling indicate that regardless of the inherently different metabolic fingerprint and genetic background of the two prostate and one breast cancer cell lines, changes in the metabolic signatures induced by the drug treatments demonstrate commonalities which are probably associated with the PI3K/Akt pathway and downstream modulation of HIF-1α. This evidence concerns the gene HIF1A and breast carcinoma.